


	M.Pharm Pharmaceutics Program outcome (MPH)			
	PO1(MPH): To Understand the principles of novel drug delivery system and apply the same for the fabrication of cost effective,			
PO1(MPH)	efficacious, and patient compliant dosage form.			
	PO2(MPH): To Understand the concepts of pre-formulation and its importance in developing a quality, efficacious, safe and stable			
PO2(MPH)	dosage form and gain knowledge in performing various analytical techniques using different equipments and instruments.			
	PO3(MPH): To Gain knowledge of drug and cosmetics regulatory process in India and other countries. To comprehend the			
	computer aided drug development process using various PK-PD soft wares and understand the basic concepts of bio			
PO3(MPH)	pharmaceutics & pharmacokinetics and its Problem solving techniques.			
	PO4(MPH): To Attain hands-on training in handling various analytical equipment; perform pre-formulation studies, and			
	formulation of cosmetics and novel drug delivery system, usage of pharmacokinetics softwares and hands-on training in the			
	formulation of cosmetics and cosmoceuticals. Ability to understand research methodology and conduct research work and its			
PO4(MPH)	presentation			

M.Pharm Pharmaceutics Course outcome

M.Pharm Pharmaceutics Course outcome			
ID	OUTCOME		
CO1(MPH)	To understand theoretical and practical skills of handling various instruments		
CO2(MPH)	To gain knowledge in formulation and evaluation of novel drug delivery systems. To get hands-on training in formulating,		
	systemic and targeted novel drug delivery system.		




CO3(MPH)	Able to understand the elements of pre-formulation studies, optimisation of formulations, GMP and pilot plant techniques. To
	study the compression & compaction of tablets and consolidation parameters using various statistical tests.
CO4(MPH)	Gain knowledge in documentation and drug approval process in India and abroad. Understand dossiers and protocols related
	to Clinical and non-clinical drug development
CO5(MPH)	Ability to analyse drugs and formulations using various instruments. Ability to perform various pre-formulation studies. Gain
	knowledge in formulation and evaluation of novel dosage forms.
CO6(MPH)	To gain knowledge in understanding basics of bio pharmaceutics & pharmacokinetics, its calculations and applications. To
	understand the concept of in vitro, in vivo drug product performances.
CO7(MPH)	To understand the basics of computers in drug development. To understand the principles of QBD, optimisation of
	formulations, computer simulations, biopharmaceutical characterisation and artificial intelligence in drug design.
CO8(MPH)	To understand the formulation and evaluation of synthetic & herbal cosmetics and cosmeceuticals. Gain knowledge in the
	cosmetics regulatory process, biological aspects of skin & skin care products. Able to understand various pharmaceutical
	automation
	ability to understand research methodologies, biostatistical tools that can be employed in research, various medical care
CO9(MPH)	protocols, CPCSEA guidelines for laboratory animals.
CO10(MPH)	Ability to understand the details of a journal and its importance along with protocols of writing a journal.
	Ability to acquire freedom to express their ideas and thoughts of their perspective in choosing a project of their own interest
CO11(MPH)	under the supervision of respective guides.
	Ability to explain their research projects through seminars, along with their thesis, in partial fulfillment for the award of their
CO12(MPH)	post-graduation degree



M.Pharm Pharmaceutics - Program outcome and course outcome Map


		I- SEMESTER		
Code:MPC:101	T - Sub: MODERN PHARM	MACEUTICAL ANALYTI	CAL TECHNIQUES (MPA	T)MPAT
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)		X	X	
CO2(MPH)				
CO3(MPH)				
CO4(MPH)				
CO5(MPH)		X	X	
CO6(MPH)				
CO7(MPH)				
CO8(MPH)				
CO9(MPH)				
CO10(MPH)				
CO11(MPH)				
CO12(MPH)				
	Code:MPH:1027	Γ - Sub: Drug delivery Syste	em (DDS)	
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)	X			
CO3(MPH)				
CO4(MPH)				
CO5(MPH)	X			



ub: Modern Pharmaceut	tics (MP)	
PO2(MPH)	PO3(MPH)	PO4(MPH)
Х	Х	
Х	Х	
-	· Sub: Regulatory affair:	- Sub: Regulatory affairs (RA)



	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)				
CO3(MPH)				X
CO4(MPH)				
CO5(MPH)				X
CO6(MPH)				
CO7(MPH)				X
CO8(MPH)				
CO9(MPH)				
CO10(MPH)				
CO11(MPH)				
CO12(MPH)				
	Code:MPA:105TP- Su	ib: PHARMACEUTICS Pl	RACTICAL I	·
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)	X	X		X
CO2(MPH)	X	X		X
CO3(MPH)		X		X
CO4(MPH)				
CO5(MPH)		X		X
CO6(MPH)				
CO7(MPH)				
CO8(MPH)				



CO9(MPH)		
CO10(MPH)		
CO11(MPH)		
CO12(MPH)		

		II- SEMESTER		
Code:MPH: 2	201T - Sub: MOLECULAR P	HARMACEUTICS (NANO	TECHNOLOGY & TAR	GETED DDS) (NTDS)
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)	X			Х
CO3(MPH)				
CO4(MPH)				
CO5(MPH)				
CO6(MPH)				
CO7(MPH)				
CO8(MPH)				
CO9(MPH)				
CO10(MPH)				
CO11(MPH)				
CO12(MPH)				
C	Code:MPH:202T - Sub: Adva	nced Biopharmaceutics	and pharmacokinetics	(ABBK)
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				



CO2(MPH)				
CO3(MPH)				
CO4(MPH)				
CO5(MPH)				
CO6(MPH)			X	
CO7(MPH)			Х	
CO8(MPH)				
CO9(MPH)				
CO10(MPH)				
CO11(MPH)				
CO12(MPH)				
	Code:MPH:20.	3T- Sub: Computer aided di	rug design (CADD)	
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO1(MPH) CO2(MPH)				
CO2(MPH)				
CO2(MPH) CO3(MPH)				
CO2(MPH) CO3(MPH) CO4(MPH)				
CO2(MPH) CO3(MPH) CO4(MPH) CO5(MPH)				X
CO2(MPH) CO3(MPH) CO4(MPH) CO5(MPH) CO6(MPH)				X X X
CO2(MPH) CO3(MPH) CO4(MPH) CO5(MPH) CO6(MPH) CO7(MPH)				




CO11(MPH)				
CO12(MPH)				
	Code:MPH:2	04T- Sub: cosmetics and co	smeceuticals (CC)	
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)				
CO3(MPH)				
CO4(MPH)				
CO5(MPH)				
CO6(MPH)				
CO7(MPH)				
CO8(MPH)			Х	Х
CO9(MPH)				
CO10(MPH)				
CO11(MPH)				
CO12(MPH)				
	Code:MPA:205	TP- Sub: PHARMACEUTI	CS PRACTICAL II	
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)	X	Х		X
CO3(MPH)				
CO4(MPH)				
CO5(MPH)	X	Х		Х



CO6(MPH)	X	X		X
CO7(MPH)	X	X		Х
CO8(MPH)	X	X		X
CO9(MPH)				
CO10(MPH)				
CO11(MPH)				
CO12(MPH)				
		III- SEMESTER		
	Code:MPH:301T - Sub	Research methodology and B	iostatistics (RMB)	
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)				
CO3(MPH)				
CO4(MPH)				
CO5(MPH)				
CO6(MPH)				
CO7(MPH)				
CO8(MPH)				
CO9(MPH)				Х
CO10(MPH)				Х
CO11(MPH)				
CO12(MPH)				
	Discussion/	Presentation (Proposal Present	tation)	



	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)				
CO3(MPH)				
CO4(MPH)				
CO5(MPH)				
CO6(MPH)				
CO7(MPH)				
CO8(MPH)				
CO9(MPH)				
CO10(MPH)				X
CO11(MPH)				X
CO12(MPH)				X
		Research Work		
	PO1(MPH)	PO2(MPH)	PO3(MPH)	PO4(MPH)
CO1(MPH)				
CO2(MPH)				
CO3(MPH)				
CO4(MPH)				
CO5(MPH)				
CO6(MPH)				
CO7(MPH)				
CO8(MPH)				



CO9(MPH)		
CO10(MPH)		X
CO11(MPH)		Х
CO12(MPH)		



SPECIFIC LEARNING OUTCOMES (SLO)- M.PHARM-PHARMACEUTICS- I Semester

M.PHARM-PHARMACEUTICS (MPH)						
	Code:101T - MODERN PHARMACEUTICAL ANALYTICAL TECHNIQUES (MPAT)					
ID	Unit / Topic	Outcome statement				
		Ability to understand principles and instrumentation of UV-Vis, IR, Flame emission spectroscopy				
SLO1(MPH)	Spectroscopy	along withspectro fluorometry and their applications				
		To understand Principles, Instrumentation, Solvent requirements, chemical shifts of NMR; briefly				
SLO2(MPH)	NMR spectroscopy	about FT-NMR and 13CNMR				
		To understande Mass Spectroscopy, Ionization techniques, Fragmentation Rules, Mass Analysers,				
SLO3(MPH)	Mass spectroscopy	Applications				
		Ability to understand Detailed study of various types of Chromatographies (TLC, HPLC, HPTLC,				
SLO4(MPH)	Chromatography	GC, UPLC, etc), Electrophoresis, X-ray Crystallography				
		To know about methods of advanced Instrumentation of Potentiometry and Thermal techniques				
SLO5(MPH)	Immunological assays	(DSC, DTA, TGA)				
		CODE:102T- DRUG DELIVERY SYSTEM (DDS)				
	Sustained Release(SR)					
	and Controlled Release					
SLO1(DDS)	(CR) formulations	Understand basic concepts of novel drug delivery system				
	Sustained Release(SR)					
	and Controlled Release					
SLO2(DDS)	(CR) formulations	Understand the principles of personalised medicines				
	Rate Controlled Drug					
SLO3(DDS)	Delivery Systems	Ability to understand theoritical principles of activation modulated system				



	Rate Controlled Drug	
SLO4(DDS)	Delivery Systems	Gain knowledge of mathematical models of activation modulated system
	Gastro-Retentive Drug	
SLO5(DDS)	Delivery Systems	Understand basic prinicples of formulation and evaluation of gastrotetentive drug delivery system
	Occular Drug Delivery	
SLO6(DDS)	System	understand Basic concepts of ocular drug delivery system
	Transdermal Drug	able to develop various approaches for the formulation and evaluation of transdermal drug delivery
SLO7(DDS)	Delivery System	system
	Protein and Peptide	
SLO8(DDS)	Delivery	able to develop formulations of macromolecules
SLO9(DDS)	Vaccine delivery system	Understand the principles of vaccine drug delivery system
		CODE:103T- MODERN PHARMACEUTICS (MP)
SLO1(MP)	Preformulation concepts	Ability to understand elements of preformulation studies
	Optimization techniques	
SLO2(MP)	in preformualtion studies	To understand the concepts and parameters of optimisation
SLO3(MP)	Validation	Ability to understand the principles of pharmaceutical validation
	cGMP and industrial	
SLO4(MP)	management	To understand industrial business management and cGMP considerations
	Compression and	
SLO5(MP)	compaction	Ability understand the physics of tablet compression
	Study of consolidation	
SLO6(MP)	parameters	To understand the concept of dissolution and pharmacokintic parameters
		CODE:104T- REGULATORY AFFAIRS(RA)



SLO1(RA)	Documentation in	Able to Documents of various records in industry		
SLO2(RA)	pharmaceutical industry	Able to understand Drug approval process		
SLO3(RA)	Regulatory requirement	to understand the approval process for generic and new molecules		
SLO4(RA)	for product approval	to understand the various regulatory filings in various countries		
	Non clinical drug			
SLO5(RA)	development	able understand submission of IND,NDA and ANDA		
SLO6(RA)	Clinical trials	To understand clinical trial protocols		
	С	ODE:105T- PHARMACEUTICS PRACTICAL-I (PP-I)		
SLO1(PP)	Able to perform analysis of drugs using various analytical techniques			
SLO2(PP)	Able to formulate and evaluate novel drug delivery system			
SLO3(PP)	Able to perform preformulation studies for API			
SLO4(PP)	Able to understand differen	nt types of drug kinetics and its calculations		

SPECIFIC LEARNING OUTCOMES (SLO)- M.PHARM-PHARMACEUTICS- II Semester

	M.PHARM-PHARMACEUTICS (MPH)				
Co	Code:201T - MOLECULAR PHARMACEUTICS (NANO TECHNOLOGY & TARGETED DDS) (NTDS)				
ID	Unit / Topic	Outcome statement			
	Targeted drug delivery				
	system & Targeting				
SLO1(NTDS)	SLO1(NTDS) methods To understand the principles and concepts of targeted drug delivery systems				
	Microcapsules and				
SLO2(NTDS)	SLO2(NTDS) microspheres To prepare and evaluate novel vesicular drug delivery system and microshperes				



	Pulmonary drug	
SLO3(NTDS)	delivery system	To understand the concepts of pulmonary drug delivery system
	Nucleic acid based	
SLO4(NTDS)	drug delivery system	To understand the principles of nuclear drug delivery sytem
	Biodistribution and	
SLO5(NTDS)	pharmacokinetics	To understand the theory of biodistribution and pharmacokinetics of antisense molecules
	CODE:202T- ADVA	NCED BIOPHARMACEUTICS AND PHARMACOKINETICS (ABPPK)
	Drug absorption from	
SLO1(ABPPK)	GI tract	To understand the basic concepts in biopharmaceutics and pharmacokinetics.
	Biopharmaceutical	
	consideration I drug	ability touse raw data and derive the pharmacokinetic models and parameters the best describe the
SLO2(ABPPK)	product design	process of drug absorption, distribution, metabolism and elimination.
	Drug product	
SLO3(ABPPK)	performance invivo	To critically evaluate of biopharmaceutic studies involving drug product equivalency.
		Ability to design and evaluate of dosage regimens of the drugs using pharmacokinetic and
SLO4(ABPPK)	Pharmacokinetics	biopharmaceutic parameters.
	Application of	Ability to derive potential clinical pharmacokinetic problems and understand the application of
SLO5(ABPPK)	Pharmacokinetics	pharmacokinetics of different dosage forms
	CO	DE:203T- COMPUTER AIDED DRUG DESIGN (CADD)
	Computers in	
	pharmaceutical	
	research in	
SLO1(CADD)	development	To understand the usage of computers in pharmaceutical research and QBD principles in industry



	Computationl	
	modelling of drug	
SLO2(CADD)	disposition	to understand the use of computers in drug disposition modeling and and preclinical development
	Computer aided	
	formulation	
SLO3(CADD)	development	formulations using various softwares and techniques
	Computer aided	
	biopharmaceutical	
SLO4(CADD)	charaterization	ability to understand the use of Computers in clinical development
	Artifical intellingence,	
SLO5(CADD)	Robotics and CFD	able to know pharmaceutical automation
	C	CODE:204T- COSMETICS AND COSMECEUTICALS
	Computers in	
	pharmaceutical	
	research in	
SLO1(CADD)	development	To understand the usage of computers in pharmaceutical research and QBD principles in industry
	Computationl	
	modelling of drug	
SLO2(CADD)	disposition	To understand the use of computers in drug disposition modeling and and preclinical development
	Computer aided	
	formulation	
SLO3(CADD)	development	Formulations using various softwares and techniques
	Computer aided	
SLO4(CADD)	biopharmaceutical	Ability to understand the use of Computers in clinical development



	charaterization			
	Artifical intellingence,			
SLO5(CADD)	Robotics and CFD	Able to know pharmaceutical automation		
	CODE:205T- PHARMACEUTICS PRACTICAL-I (PP-II)			
SLO1(PPII)	Able to prepare and evaluate various novel drug delivery system			
SLO2(PPII)	Able to perform various biopharmaceutical and pharmacokinetic experiments and calculations			
SLO3(PPII)	PPII) Able to use various statistical and DoE softwares for optimisation of formulations			
SLO4(PPII)	To design, formulate an	d evaluate cosmetics and cosmeceutical preparations		

M.PHARM PHARMACEUTICS (MPH) - III SEMESTER Code:301T - RESEARCH METHODOLOGY AND BIO STATISTICS				
ID	ID Unit/Topic Outcome statement			
SLO1(RMB)	SLO1(RMB) Unit I To Understand General research methodology			
SLO2(RMB)	SLO2(RMB) Unit II Ability to acquire knowledge in Biostatistics			
SLO3(RMB)	SLO3(RMB) Unit III Ability to Detail protocols of Medical research			
SLO4(RMB)	SLO4(RMB) Unit IV To have Clear perspective of CPCSEA guidelines for laboratory animal facilities			
SLO5(RMB)	LO5(RMB) Unit V To understand the declaration of Helsinki rule, additional principles combined with medical care			

M.PHARM-PHARMACEUTICS- I-SEMESTER						
	CO1	CO2	CO3	CO4	CO5	CO6
SLO1(MPAT)	X					
SLO2(MPAT)						
SLO3(MPAT)						



SLO4(MPAT)					
SLO5(MPAT)					
SLO1(DDS)	X			Χ	
SLO2(DDS)	X			Χ	
SLO3(DDS)	X			Χ	
SLO4(DDS)	X			Χ	
SLO5(DDS)	X			X	
SLO6(DDS)	X			X	
SLO7(DDS)	X			Χ	
SLO8(DDS)	X			X	
SLO9(DDS)	X			Χ	
SLO1(MP)		X		X	
SLO2(MP)		X			
SLO3(MP)		X			
SLO4(MP)		X			
SLO5(MP)		X			
SLO6(MP)		X			
SLO7(MP)		X			
SLO8(MP)		X			
SLO9(MP)		X			
SLO1(RA)			X		
SLO2(RA)			X		
SLO3(RA)			X		



SLO4(RA)				X	X
SLO5(RA)				X	
SLO6(RA)				X	
SLO1(PP-I)	X				
SLO2(PP-I)		X			
SLO3(PP-I)			X		
SLO4(PP-I)					X

II-SEMESTER (Contraction of the second										
	CO1	CO2	CO3	CO4	CO5	CO6	CO7	CO8	CO9	
SLO1(NTDS)		X								
SLO2(NTDS)		X								
SLO3(NTDS)		X								
SLO4(NTDS)		X								
SLO5(NTDS)		X				X				
SLO1(ABPPK)						X	X			
SLO2(ABPPK)						X	Χ			
SLO3(ABPPK)						Χ	Χ			
SLO4(ABPPK)						Χ	Χ			
SLO5(ABPPK)						Χ	Χ			
SLO1(CADD)						X				
SLO2(CADD)						X				
SLO3(CADD)						X				



SLO4(CADD)			2	X						
SLO5(CADD)				X						
SLO1(CC)					X					
SLO2(CC)					X					
SLO3(CC)					X					
SLO4(CC)					X					
SLO5(CC)					X					
SLO1(PP-II)	X									
SLO2(PP-II)			2	X						
SLO3(PP-II)				X						
SLO4(PP-II)					X					
III SEMESTER										
SLO1(RMB)						X				
SLO2(RMB)						Χ				
SLO3(RMB)						X				
SLO4(RMB)						X				
SLO5(RMB)						Χ				